Ähnliche Pins
DePuy Synthes trennt sich von Johnson & Johnson
GESCHÄTZT71 % SICHERHEITin 281 TagenDas 10-Q von J&J für das am 28. Juni 2026 endende Quartal strebt einen „Abschluss innerhalb von 18 bis 24 Monaten nach der ursprünglichen Ankündigung" vom 14. Oktober 2025 an (Mitte April bis Mitte Oktober 2027), und Finanzchef Joseph Wolk sagte im Juli, J&J sei „auf Kurs für eine Trennung Mitte 2027" (Bloomberg); „Mitte 2027" wird als Jahresmitte, also 1. Juli 2027, gelesen, was innerhalb dieses Zeitfensters liegt.[1]Das Orthopädiegeschäft von Johnson & Johnson soll als DePuy Synthes aus dem Konzern ausscheiden – per steuerfreiem Spin-off oder per Verkauf, wobei Apollo über rund 20 Milliarden Dollar verhandelt. J&J sieht sich auf Kurs für eine Trennung Mitte 2027.0.79J&J Announces Plan to Spin Off DePuy Synthes
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
BESTÄTIGT90 % SICHERHEITvor 344 TagenThe release is datelined "NEW BRUNSWICK, NJ, October 14, 2025 - Johnson & Johnson ... today announced the Company's intent to separate its Orthopaedics business"; it states no time of day (CNBC's[3] report was up at 6:29 a.m. EDT and J&J's X post at 6:40 a.m. EDT), so the pin is the all-day 14 October.Johnson & Johnson said it would separate its roughly $9.2 billion-a-year orthopaedics business into a standalone company called DePuy Synthes within 18 to 24 months, and named former Smith & Nephew chief Namal Nawana to run it.0.73J&J Completes Its $1 Billion Acquisition of Firefly Bio
BESTÄTIGT87 % SICHERHEITvor 56 Tagen"NEW BRUNSWICK, NJ (July 29, 2026) - Johnson & Johnson (NYSE: JNJ[1][3]) today announced the successful completion of its acquisition of Firefly Bio, Inc. ... for $1 billion in cash"; the 8-K furnishing it gives "Date of report (Date of earliest event reported): July 29, 2026".Johnson & Johnson closed its $1 billion cash purchase of Firefly Bio, the South San Francisco biotech behind the Firelink degrader antibody conjugate platform for KRAS-driven and other hard-to-treat solid tumours.$1B0.63J&J Proposes $5.5 Billion Deal to Settle 76,000 Ovarian Cancer Talc Claims
BESTÄTIGT82 % SICHERHEITvor 58 TagenJ&J's release is datelined "New Brunswick, N.J. - JULY 27, 2026 - Johnson & Johnson (NYSE: JNJ[1]) ... today announced", and the copy filed as Exhibit 99.1 to its 8-K is marked "FOR RELEASE AT 6:15PM ET", 22:15 UTC in EDT.Johnson & Johnson announced a proposed resolution of its remaining ovarian talc litigation, about 76,000 claims, with a $5.5 billion commitment paid per claim - no more than $3 billion in 2027 and nothing more before 2028 - if at least 95% of claimants take part.$5.5B0.61Abbott Agrees to Buy Exact Sciences for $21 Billion
BESTÄTIGT86 % SICHERHEITvor 307 TagenThe release is datelined "ABBOTT PARK, Ill., and MADISON, Wis., Nov. 20, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement".[1]Abbott agreed to buy Cologuard maker Exact Sciences for $105 a share in cash, a total equity value of about $21 billion, to enter cancer screening and precision oncology diagnostics.$21B0.60Internationale Raumstation vor kontrolliertem Absturz
GEPLANT77 % SICHERHEITin 4,3 JahrenAls geplant angegeben, laut Quelle: „Die NASA[3] und ihre internationalen Partner planen, das Weltraumlabor um 2030 oder kurz danach gezielt zum Absturz zu bringen.“Die NASA will die 25 Jahre alte ISS ausmustern und sie mit einem eigens gebauten SpaceX-Deorbit-Fahrzeug in eine abgelegene Region des Südpazifiks lenken.$843M0.59Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion
BESTÄTIGT87 % SICHERHEITvor 120 TagenLilly's release is datelined "INDIANAPOLIS, May 26, 2026" and says Lilly "today announced agreements to acquire three companies".[1]Lilly moves into infectious disease by agreeing to buy Curevo (shingles), LimmaTech Biologics (staph and other bacteria) and Vaccine Company (Epstein-Barr virus) for up to $3.83 billion combined in cash.$3.8B0.58Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion
BESTÄTIGT88 % SICHERHEITvor 23 TagenThe release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".[1]Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.$2.9B0.58Inside Tesla's $5 Billion Gigafactory - Visual Capitalist
The $5 Billion Tesla Gigfactory will set a new precedent for economies of scale in battery production, creating demand for graphite, cobalt, and lithium. The name gigafactory comes from the plant's planned annual battery production capacity of 35 gigawatt-hours, which Tesla said on Wednesday it would achieve by 2018.$5B0.58Huang: $1 trillion in Blackwell and Vera Rubin orders through 2027
BESTÄTIGT90 % SICHERHEITvor 191 TagenCNBC's[1] 16 March 2026 coverage of the GTC 2026 keynote reports the remark.At GTC 2026, Huang said he expects purchase orders for Blackwell and Vera Rubin to reach $1 trillion through 2027, up from the $500 billion outlook given the previous year.0.58Babcock & Wilcox Gets Go-Ahead on $2.4B Base Electron Power Plant
BESTÄTIGT87 % SICHERHEITvor 203 TagenStated as done, per babcock.com[1]: "(AKRON, Ohio - March 4, 2026) - Babcock & Wilcox ... announced today that it has received full notice to proceed on a $2.4 billion design-build agreement"; the Business Wire copy on Yahoo Finance is timestamped 11:30 UTC.Babcock & Wilcox received full notice to proceed on a $2.4 billion design-build contract with Base Electron, an Applied Digital-backed power producer, for 1.2 GW of gas-fired boiler and steam turbine capacity to supply Applied Digital AI Factory campuses.$2.4B0.58Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
BESTÄTIGT87 % SICHERHEITvor 176 TagenThe joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".[1]Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.$7.8B0.58
